$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt

$eypt Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000119312516455089 Filed on February 09, 2016

Income Statement

Concept	2015 Q4	2014 Q4
Revenue	$526.0K	$521.0K
YoY Change	0.96%	-11.99%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.040M	$1.870M
YoY Change	9.09%	9.36%
% of Gross Profit
Research & Development	$3.721M	$2.767M
YoY Change	34.48%	10.95%
% of Gross Profit
Depreciation & Amortization	$220.0K	$210.0K
YoY Change	4.76%	-8.7%
% of Gross Profit
Operating Expenses	$5.764M	$4.637M
YoY Change	24.3%	12.19%
Operating Profit	-$5.238M	-$4.116M
YoY Change	27.26%	16.24%
Interest Expense	$10.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$10.00K	$3.000K
YoY Change	233.33%	200.0%
Pretax Income	-$5.228M	-$4.113M
YoY Change	27.11%	16.19%
Income Tax	-$42.00K	-$38.00K
% Of Pretax Income
Net Earnings	-$5.186M	-$4.075M
YoY Change	27.26%	15.96%
Net Earnings / Revenue	-985.93%	-782.15%
Basic Earnings Per Share	-$0.18	-$0.14
Diluted Earnings Per Share	-$0.18	-$0.14
COMMON SHARES
Basic Shares Outstanding	29.44M shares	29.37M shares
Diluted Shares Outstanding	29.44M shares	29.37M shares

Balance Sheet

Concept	2015 Q4	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.10M	$35.70M
YoY Change	-40.9%	127.39%
Cash & Equivalents	$11.21M	$29.75M
Short-Term Investments	$9.900M	$5.900M
Other Short-Term Assets	$200.0K	$900.0K
YoY Change	-77.78%	0.0%
Inventory
Prepaid Expenses
Receivables	$600.0K	$700.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$21.86M	$37.35M
YoY Change	-41.46%	116.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$311.0K	$265.0K
YoY Change	17.36%	99.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$300.0K	$300.0K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$2.088M	$2.832M
YoY Change	-26.27%	-21.05%
TOTAL ASSETS
Total Short-Term Assets	$21.86M	$37.35M
Total Long-Term Assets	$2.088M	$2.832M
Total Assets	$23.95M	$40.18M
YoY Change	-40.39%	93.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$303.0K	$384.0K
YoY Change	-21.09%	118.18%
Accrued Expenses	$3.552M	$1.820M
YoY Change	95.16%	51.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.883M	$2.273M
YoY Change	70.83%	5.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$5.600M	$5.600M
YoY Change	0.0%	-8.2%
Total Long-Term Liabilities	$5.600M	$5.600M
YoY Change	0.0%	-8.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.883M	$2.273M
Total Long-Term Liabilities	$5.600M	$5.600M
Total Liabilities	$9.526M	$7.905M
YoY Change	20.51%	-3.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$280.8M	-$260.5M
YoY Change	7.78%	-3.82%
Common Stock	$294.3M	$29.00K
YoY Change	1014779.31%	7.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.42M	$32.28M
YoY Change
Total Liabilities & Shareholders Equity	$23.95M	$40.18M
YoY Change	-40.39%	93.0%

Cashflow Statement

Concept	2015 Q4	2014 Q4
OPERATING ACTIVITIES
Net Income	-$5.186M	-$4.075M
YoY Change	27.26%	15.96%
Depreciation, Depletion And Amortization	$220.0K	$210.0K
YoY Change	4.76%	-8.7%
Cash From Operating Activities	-$3.180M	$21.25M
YoY Change	-114.96%	-1044.44%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$20.00K
YoY Change	50.0%	100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$3.040M
YoY Change	-100.0%	-330.3%
Cash From Investing Activities	-$20.00K	-$3.060M
YoY Change	-99.35%	-333.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	330.0K	180.0K
YoY Change	83.33%	-88.89%
NET CHANGE
Cash From Operating Activities	-3.180M	21.25M
Cash From Investing Activities	-20.00K	-3.060M
Cash From Financing Activities	330.0K	180.0K
Net Change In Cash	-2.870M	18.37M
YoY Change	-115.62%	2601.47%
FREE CASH FLOW
Cash From Operating Activities	-$3.180M	$21.25M
Capital Expenditures	-$30.00K	-$20.00K
Free Cash Flow	-$3.150M	$21.27M
YoY Change	-114.81%	-1049.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34072919	shares
CY2014Q1	us-gaap	Security Deposit SecurityDeposit	150000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	32275000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29751000
CY2014Q4	psdv	Milestone Payment Received Upon Fda Approval MilestonePaymentReceivedUponFdaApproval	25000000
CY2014Q4	psdv	Warrants Weighted Average Exercise Price WarrantsWeightedAverageExercisePrice	3.67
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29627919	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29627919	shares
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	294286000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	14000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	617000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	14424000
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	342000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	59000
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	28000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	303000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3552000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280785000
CY2015Q4	us-gaap	Liabilities Liabilities	9526000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23950000
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5584000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	29000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3883000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	894000
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3000000
CY2015Q4	us-gaap	Assets Assets	23950000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000
CY2015Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	17952000
CY2015Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	573000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	311000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	9881000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	21862000
CY2015Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8071000
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9881000
CY2015Q4	us-gaap	Other Assets OtherAssets	115000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1512000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	198000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11210000
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	9890000
CY2015Q4	psdv	Collaboration Agreement Ownership Percentage In Company CollaborationAgreementOwnershipPercentageInCompany	0.063	pure
CY2015Q4	psdv	Estimated Annual Amortization Of Intangible Assets EstimatedAnnualAmortizationOfIntangibleAssets	756000
CY2015Q4	psdv	Cash And Cash Equivalents And Marketable Securities Fair Value CashAndCashEquivalentsAndMarketableSecuritiesFairValue	21100000
CY2015Q4	psdv	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	2579000
CY2015Q4	psdv	Warrants Weighted Average Exercise Price WarrantsWeightedAverageExercisePrice	3.67
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	14924000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15334000
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29412365	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29412365	shares
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	293060000
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	28000
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	735000
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	23368000
CY2015Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	384000
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	55000
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33000
CY2015Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	15835000
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	9414000
CY2015Q2	us-gaap	Other Assets OtherAssets	116000
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1925000
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	681000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19121000
CY2015Q2	psdv	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	1424000
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	744000
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2571000
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270666000
CY2015Q2	us-gaap	Liabilities Liabilities	8999000
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32367000
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5596000
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	29000
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3348000
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	945000
CY2015Q2	us-gaap	Assets Assets	32367000
CY2015Q2	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	25249000
CY2015Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	622000
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	338000
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000
CY2015Q2	us-gaap	Assets Current AssetsCurrent	29838000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.54
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	17257000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2376324	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30618144	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1016710	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29344689	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	3287000
	us-gaap	Net Income Loss NetIncomeLoss	16491000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-5000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-101000
	us-gaap	Revenues Revenues	25828000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	726000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	618000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	25245000
	us-gaap	Operating Income Loss OperatingIncomeLoss	16673000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000
	us-gaap	Royalty Revenue RoyaltyRevenue	583000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	16390000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-96000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16679000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	188000
	us-gaap	Share Based Compensation ShareBasedCompensation	726000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-69000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	14417000
	us-gaap	Operating Expenses OperatingExpenses	9155000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3065000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	235000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5551000
	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	235000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	235000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	726000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3604000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-10000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	41000
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	260000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	389000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	230000
	us-gaap	Depreciation Depreciation	57000
	psdv	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	256745	shares
	psdv	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	10000
	psdv	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	250000
	psdv	Warrants To Purchase Common Shares Outstanding And Exercisable WarrantsToPurchaseCommonSharesOutstandingAndExercisable	1176105	shares
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Operations and Basis of Presentation</b></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The accompanying condensed consolidated financial statements of pSivida Corp. and subsidiaries (the “Company”) as of December 31, 2015 and for the three and six months ended December 31, 2015 and 2014 are unaudited. Certain information in the footnote disclosures of these financial statements has been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”). These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes included in its Annual Report on Form 10-K for the fiscal year ended June 30, 2015. In the opinion of management, these statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2015, and include all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair presentation of the Company’s financial position, results of operations, comprehensive (loss) income and cash flows for the periods indicated. The preparation of financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) requires management to make assumptions and estimates that affect, among other things, (i) reported amounts of assets and liabilities; (ii) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; and (iii) reported amounts of revenues and expenses during the reporting period. The results of operations for the three and six months ended December 31, 2015 are not necessarily indicative of the results that may be expected for the entire fiscal year or any future period.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company develops sustained-release drug delivery products primarily for the treatment of chronic eye diseases. Its products deliver drugs at a controlled and steady rate for months or years. The Company has developed three of only four sustained-release products approved by the U.S. Food and Drug Administration (“FDA”) for treatment of back-of-the-eye diseases. Medidur™ for posterior uveitis, the Company’s lead product candidate, is in pivotal Phase III clinical trials, and ILUVIEN<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> for diabetic macular edema (“DME”), its lead licensed product, is sold in the U.S. and three European Union (“EU”) countries. The Company’s pre-clinical development program is focused primarily on developing products utilizing the Company’s two core technology platforms, Durasert™ and Tethadur™. The Company’s strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements as appropriate.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Medidur, the Company’s most advanced development product, is a sustained-release micro-insert designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (“posterior uveitis”). Medidur, which is designed to provide sustained treatment for three years from a single injection, is in two Phase III trials. In December 2015, the Company announced positive top-line results from the first Phase III trial, which met its primary efficacy endpoint with high statistical significance and achieved positive safety results. The second Phase III trial is ongoing. Assuming favorable results from the second trial, the Company plans to file a new drug application (“NDA”) with the FDA in the first half of 2017 based on the results from both trials, data from a short-duration utilization study of its redesigned proprietary inserter and data referenced from the Phase III trials of ILUVIEN. Due to the high level of statistical significance achieved in the first trial, the Company plans to file for EU marketing approval based on the results of that single Phase III trial rather than both trials. The Company is developing Medidur independently.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> ILUVIEN, the Company’s most recently approved product, is a sustained-release micro-insert that provides treatment of DME. Like Medidur, it is injected into the eye in an office visit and provides three years of treatment from a single injection. ILUVIEN is licensed to and sold by Alimera Sciences, Inc. (“Alimera”), and the Company is entitled to a share of the net profits (as defined) from Alimera’s sales of ILUVIEN on a quarter-by-quarter, country-by-country basis. ILUVIEN was launched in the U.S. in late February 2015, where it is indicated for the treatment of DME in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure. ILUVIEN has been commercially available in the United Kingdom and Germany since June 2013 and in Portugal since January 2015. ILUVIEN has marketing approvals in 17 EU countries for the treatment of chronic DME considered insufficiently responsive to available therapies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company’s FDA-approved Retisert<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">®</sup> is an implant that provides sustained release treatment of posterior uveitis for approximately two and a half years. It is licensed to Bausch & Lomb, and the Company receives royalties from its sales.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> The Company’s pre-clinical development program is focused on developing products using its Durasert™ and Tethadur™ technology platforms to deliver drugs and biologics to treat wet and dry age-related macular degeneration (“AMD”), glaucoma, osteoarthritis and other diseases.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company has a history of operating losses and has financed its operations primarily from the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners and from proceeds of sales of its equity securities. The Company believes that its cash, cash equivalents and marketable securities of $21.1 million at December 31, 2015, together with the estimated net proceeds of approximately $16.4 million from an underwritten public offering of common shares in January 2016, as well as expected cash inflows under existing collaboration agreements, will enable the Company to maintain its current and planned operations (including its two Medidur Phase III clinical trials) into the fourth quarter of calendar year 2017. This estimate excludes any potential future receipts from the commercialization of ILUVIEN. The Company’s ability to fund its planned operations beyond then, including completion of clinical development of Medidur, is expected to depend on the amount and timing of cash receipts under the ILUVIEN collaboration agreement, as well as proceeds from any future collaboration or other agreements and/or financing transactions.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> New accounting pronouncements are issued periodically by the Financial Accounting Standards Board (“FASB”) and are adopted by the Company as of the specified effective dates. Unless otherwise disclosed below, the Company believes that recently issued and adopted pronouncements will not have a material impact on the Company’s financial position, results of operations and cash flows or do not apply to the Company’s operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In May 2014, the FASB issued Accounting Standards Update No. 2014-09, <i>Revenue from Contracts with Customers</i> (Topic 606) (“ASU 2014-09”), which requires an entity to recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP. In August 2015, the FASB issued ASU 2015-14, which officially deferred the effective date of ASU 2014-09 by one year, while also permitting early adoption. As a result, ASU 2014-09 will become effective on July 1, 2018, with early adoption permitted on July 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the impact this standard will have on its financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In August 2014, the FASB issued ASU 2014-15, <i>Presentation of Financial Statements – Going Concern</i>. ASU 2014-15 provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7667000
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.80	pure
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6254526	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001314102
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	626605	shares
	dei	Entity Registrant Name EntityRegistrantName	pSivida Corp.
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29426224	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P2Y
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29426224	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0183	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.74
	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0197	pure
	dei	Trading Symbol TradingSymbol	PSDV
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.76	pure
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5843000
	us-gaap	Net Income Loss NetIncomeLoss	-10119000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-4000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-51000
	us-gaap	Revenues Revenues	992000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	888000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-520000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	322000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10222000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000
	us-gaap	Royalty Revenue RoyaltyRevenue	670000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10170000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-47000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10202000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-83000
	us-gaap	Share Based Compensation ShareBasedCompensation	888000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-17000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7911000
	us-gaap	Operating Expenses OperatingExpenses	11214000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-574000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	338000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7203000
	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	338000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	338000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	888000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4011000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-8000
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	68000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	382000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	548000
	us-gaap	Depreciation Depreciation	59000
	psdv	Warrants Outstanding Weighted Average Remaining Contract Life WarrantsOutstandingWeightedAverageRemainingContractLife	P10M24D
	psdv	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	0	shares
	psdv	Marketable Securities Weighted Average Maturity MarketableSecuritiesWeightedAverageMaturity	P3M9D
	psdv	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	5305000
	psdv	Warrants To Purchase Common Shares Outstanding And Exercisable WarrantsToPurchaseCommonSharesOutstandingAndExercisable	1176105	shares
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2014Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5667054	shares
	psdv	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	4000
CY2014Q4	psdv	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	0	shares
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2015Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6254526	shares
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29436874	shares
CY2014Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29366669	shares
CY2014Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2014Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29366669	shares
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-4075000
CY2014Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-2000
CY2014Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-48000
CY2014Q4	us-gaap	Revenues Revenues	521000
CY2014Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	164000
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4116000
CY2014Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000
CY2014Q4	us-gaap	Royalty Revenue RoyaltyRevenue	357000
CY2014Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4123000
CY2014Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-46000
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4113000
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-38000
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	4637000
CY2014Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2767000
CY2014Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	417000
CY2014Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1870000
CY2014Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	193000
CY2015Q4	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015Q4	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P2Y
CY2015Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29436874	shares
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-5186000
CY2015Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-6000
CY2015Q4	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-25000
CY2015Q4	us-gaap	Revenues Revenues	526000
CY2015Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	142000
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-5238000
CY2015Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10000
CY2015Q4	us-gaap	Royalty Revenue RoyaltyRevenue	384000
CY2015Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5211000
CY2015Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-19000
CY2015Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5228000
CY2015Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-42000
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	5764000
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2043000
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3721000
CY2015Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	483000
CY2015Q4	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	190000
CY2015Q4	psdv	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	0	shares

Files In Submission

Name	View Source	Status
0001193125-16-455089-index-headers.html	Edgar Link	pending
0001193125-16-455089-index.html	Edgar Link	pending
0001193125-16-455089.txt	Edgar Link	pending
0001193125-16-455089-xbrl.zip	Edgar Link	pending
d120199d10q.htm	Edgar Link	pending
d120199dex311.htm	Edgar Link	pending
d120199dex312.htm	Edgar Link	pending
d120199dex321.htm	Edgar Link	pending
d120199dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
psdv-20151231.xml	Edgar Link	completed
psdv-20151231.xsd	Edgar Link	pending
psdv-20151231_cal.xml	Edgar Link	unprocessable
psdv-20151231_def.xml	Edgar Link	unprocessable
psdv-20151231_lab.xml	Edgar Link	unprocessable
psdv-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt

2015 Q4 Form 10-Q Financial Statement

#000119312516455089 Filed on February 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYPT EyePoint Pharmaceuticals, Inc. Stock $eypt

2015 Q4 Form 10-Q Financial Statement

#000119312516455089 Filed on February 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYPT
EyePoint Pharmaceuticals, Inc. Stock $eypt